Cardiovascular Medicine, Volume 15, Issue 5

The Swiss Heart Foundation awards an annual prize of Swiss Francs 20 000.– for one or several outstanding publications / accepted manuscripts of scientific research in the field of the prevention, diagnosis and/or treatment of cardiovascular diseases...

Ever since their introduction in the middle of the 20th century, vitamin K antagonists (VKAs) have been used in the treatment and prevention of thromboembolic diseases, especially for venous thromboembolism and stroke prevention in atrial fibrillatio...

Novel oral anticoagulants such as dabigatran which specifically target thrombin, and rivaroxaban and apixaban which are activated factor X inhibitors are in the process of being approved for use in Switzerland to lower the risk of stroke in patients...

Atrial fibrillation is the most common sustained cardiac arrhythmia. Thromboembolic events related to atrial fibrillation result in significant morbidity, mortality and increases in the cost of healthcare. For decades, vitamin Kantagonists have been...

Acute coronary syndrome (ACS) and its sequelae continue to be the major cause of death in developed countries resulting in a high toll of fatalities and health care expenditure. The treatment of ACS has dramatically evolved over the last decade leadi...

Thrombin plays an essential role in haemostasis and thrombosis; therefore, anticoagulant strategies focus on direct or indirect inhibition of thrombin or factor Xa. Over the last 60 years, key players in antithrombotic treatment have been unfractiona...